Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06356727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

Study acronym: MICROREV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 10, 2024 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF \<40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.
Trial Details
NCT Number NCT06356727
Lead Sponsor Azienda Ospedaliera Universitaria Integrata Verona
Collaborators: Abbott Medical Devices
Conditions
(from sponsor)
Heart Failure, Left Ventricular Dysfunction, Idiopathic Dilated Cardiomyopathy
Related terms Cardiomyopathy, Dilated, Heart Failure, Ventricular Dysfunction, Left
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov